• The CEPir is based on an improved method for magnetic cell separation. The CEPir’s contact free design holds tagged cells of interest in stasis, yielding highly viable cells suitable for any downstream use. The CEPir’s flow through technology and novel design

    Learn more

  • The CEP is a flow through technology that yields a larger number of viable cells, with increased purity in comparison to leading separation methods.  The CEP enables effective rare cell isolation of 1 in 109 cells with excellent recovery, suitable for downstream applications

    Learn more

  • CEP's separation capabilities are unsurpassed with high purity, recovery and viability, enabling breakthroughs in various life science fields. Partner with us to jointly develop groundbreaking applications over our advanced rare cell isolation platform, the CEPir.

    Learn More

  • BioCEP mourns the loss of its founder and dear friend, Mr. Aharon Lamish.

    Pontifax Ltd. and BRM Ltd. lead series A round of $5.33 million.

    Nir Nimrodi appointed chairman of the board

    BioCEP to enters  joint research collaborations with Institut Gustave-Roussy and with Meir Medical Center.

    BioCEP awarded 0.5 M Euro from the FP7 framework 

About BioCep

Founded in 2006, BioCEP Ltd., a privately owned, Israeli company is focused on the development of cutting-edge technologies for cell isolation. BioCEP develops, manufactures and sells these products to its customers, worldwide. Its patented Cell Enrichment Process is incorporated in the CEPir (Cell Enrichment Process for Isolation of Rare Cells) cell isolation device enabling effective immunomagnetic cell isolation for R&D. The CEPir  isolates rare cells at high purity and recovery rates offering an alternative to inferior traditional solutions. BioCEP is developing novel clinical and diagnostic applications over its advanced cell isolation platform.

Watch Our Video

Movie_Icon

The CEPir is a research use only device and is not intended for clinical or therapeutic use.